The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 03, 2023

Filed:

Dec. 12, 2016
Applicant:

Research Institute AT Nationwide Children's Hospital, Columbus, OH (US);

Inventors:

Christopher Breuer, New Albany, OH (US);

Cameron Best, Blacklick, OH (US);

Robert Strouse, Columbus, OH (US);

Narutoshi Hibino, Towson, MD (US);

Yong Ung-Lee, Columbus, OH (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61L 27/38 (2006.01); A61L 27/18 (2006.01); A61L 27/20 (2006.01); A61L 27/24 (2006.01); A61L 27/50 (2006.01); D01D 5/00 (2006.01); B33Y 10/00 (2015.01); B33Y 80/00 (2015.01); A61L 27/54 (2006.01); A61L 27/58 (2006.01);
U.S. Cl.
CPC ...
A61L 27/3834 (2013.01); A61L 27/18 (2013.01); A61L 27/20 (2013.01); A61L 27/24 (2013.01); A61L 27/507 (2013.01); A61L 27/54 (2013.01); A61L 27/58 (2013.01); B33Y 10/00 (2014.12); B33Y 80/00 (2014.12); D01D 5/0076 (2013.01); A61L 2300/41 (2013.01); A61L 2300/414 (2013.01); A61L 2300/416 (2013.01);
Abstract

It has been established that optimizing cell seeding onto tissue engineering vascular grafts (TEVG) is associated with reduced inflammatory responses and reduced post-operative stenosis of TEVG. Cell seeding increased TEVG patency in a dose dependent manner, and TEVG patency improved when more cells were seeded, however duration of incubation time showed minimal effect on TEVG patency. Methods of engineering patient specific TEVG including optimal numbers of cells to maintain graft patency and reduce post-operative stenosis are provided. Closed, single-use customizable systems for seeding TEVG are also provided. Preferably the systems are custom-designed based on morphology of the patient specific graft, to enhance the efficacy of cell seeding.


Find Patent Forward Citations

Loading…